- Home
- ORGO vs HQL Comparison
ORGO vs HQL Comparison
Compare ORGO & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORGO | HQL |
|---|---|---|
| Founded | 1985 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.4M | 510.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORGO | HQL |
|---|---|---|
| Price | $4.80 | $17.08 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 120.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $465,218,000.00 | N/A |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | ★ 2.24 | N/A |
| 52 Week Low | $2.61 | $11.34 |
| 52 Week High | $7.08 | $14.37 |
Technical Indicators
Market Signals| Indicator | ORGO | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 51.70 |
| Support Level | $4.66 | $17.03 |
| Resistance Level | $5.83 | $17.35 |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 18.13 | 27.61 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.